Strategies to improve outcomes in esophageal adenocarcinoma

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128
   PubMed Web of Science ®Google Scholar
• Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005;92(3):169-90
   Web of Science ®Google Scholar
• Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008;103(11):2694-9
   PubMed Web of Science ®Google Scholar
• Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012;21(1):36-51
   PubMed Web of Science ®Google Scholar
• Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010;107(5):2177-82
   Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92(3):549-55
   PubMed Web of Science ®Google Scholar
• Lambert R, Hainaut P. The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Pract Res Clin Gastroenterol 2007;21(6):921-45
   PubMed Web of Science ®Google Scholar
• Law S, Wong J. Changing disease burden and management issues for esophageal cancer in the Asia-Pacific region. J Gastroenterol Hepatol 2002;17(4):374-81
   Google Scholar
• Clinical Effectiveness Unit R, AUGIS, BSG, NCASP. National Oesophago-Gastric Cancer Audit. National Report. The NHS Information Centre, Leeds, UK; 2010 IC15100510
   Google Scholar
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013;381(9864):400-12
   PubMed Web of Science ®Google Scholar
• Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 2002;95(7):1434-43
   PubMed Web of Science ®Google Scholar
• D’Amico TA. Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007;1(5):188-96
   Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340(11):825-31
   PubMed Web of Science ®Google Scholar
• Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3(9):676-84
   PubMedGoogle Scholar
• Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10(10):1055-62
   PubMed Web of Science ®Google Scholar
• Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21(11):953-6
   PubMedGoogle Scholar
• Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143(5):1179-87. e1-3
   PubMed Web of Science ®Google Scholar
• Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45(5):478-86
   PubMed Web of Science ®Google Scholar
• Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol 2008;295(2):G211-18
   PubMed Web of Science ®Google Scholar
• Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002;16(4):671-3
   Google Scholar
• Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365(15):1375-83
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Savarino E, Manno M, et al. Reflux patterns in patients with short-segment Barrett’s oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;30(5):508-15
   Google Scholar
• Farre R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 2008;57(10):1366-74
   PubMed Web of Science ®Google Scholar
• Farre R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010;59(2):164-9
   PubMed Web of Science ®Google Scholar
• Cronin J, Alhamdani A, Griffiths AP, et al. In vitro and ex vivo models of extended reflux exposure demonstrate that weakly acidic mixed reflux heightens NF-kB-mediated gene expression. Dis Esophagus 2010. [Epub ahead of print]
   Google Scholar
• Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther 1998;12(9):893-7
   Google Scholar
• El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2004;99(10):1877-83
   PubMedGoogle Scholar
• Johnson DA, Oldfield EC 4th. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 2013;11(5):458-64. quiz e37-8
   PubMed Web of Science ®Google Scholar
• Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 2003;98(11):2390-4
   PubMed Web of Science ®Google Scholar
• Lofdahl HE, Lu Y, Lagergren P, Lagergren J. Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg 2013;257(4):579-82
   Google Scholar
• Babar M, Ennis D, Abdel-Latif M, et al. Differential molecular changes in patients with asymptomatic long-segment Barrett’s esophagus treated by antireflux surgery or medical therapy. Am J Surg 2010;199(2):137-43
   Google Scholar
• Martinez de Haro LF, Ortiz A, Parrilla P, et al. Long-term follow-up of malignancy biomarkers in patients with Barrett’s esophagus undergoing medical or surgical treatment. Ann Surg 2012;255(5):916-21
   Google Scholar
• Cadiere GB, Van Sante N, Graves JE, et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 2009;23(5):957-64
   Google Scholar
• Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013;368(8):719-27
   Google Scholar
• Rodriguez L, Rodriguez P, Gomez B, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease. Endoscopy 2013;45(8):595-604
   Google Scholar
• Rodriguez L, Rodriguez P, Gomez B, et al. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc 2013;27(4):1083-92
   Google Scholar
• Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124(1):47-56
   PubMed Web of Science ®Google Scholar
• England PH. Be clear on cancer: Public Health England. Available from: http://campaigns.dh.gov.uk/category/beclearoncancer/ [Last accessed 20 January 2014]
   Google Scholar
• Varghese S, Cowie A, Underwood TJ, Fitzgerald RC. Barrett’s oesophagus - diagnosis and management. 2013. Available from: http://learning.bmj.com/learning/module-intro/barrett’s-oesophagus – diagnosis-and-management-.html?moduleId=10045036 [Last accessed 20 January 2014]
   Google Scholar
• Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol 2013;30(3):596
   Web of Science ®Google Scholar
• Noble F, Nolan L, Bateman AC, et al. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013;19(48):9282-93
   Google Scholar
• Schlansky B, Dimarino AJ Jr, Loren D, et al. A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther 2006;23(5):587-93
   Google Scholar
• Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008;15(11):3278-88
   PubMed Web of Science ®Google Scholar
• Wang VS, Hornick JL, Sepulveda JA, et al. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett’s esophagus: a 20-year experience. Gastrointest Endosc 2009;69(4):777-83
   Google Scholar
• Modiano N, Gerson LB. Barrett’s esophagus: incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag 2007;3(6):1035-145
   Google Scholar
• Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168(3):237-49
   PubMed Web of Science ®Google Scholar
• Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ 2010;341:c4372
   PubMedGoogle Scholar
• Varghese S, Lao-Sirieix P, Fitzgerald RC. Identification and clinical implementation of biomarkers for Barrett’s esophagus. Gastroenterology 2012;142(3):435-41. e2
   Google Scholar
• Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance. Clin Cancer Res 2007;13(2 Pt 1):659-65
   Google Scholar
• Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2(10):899-905
   PubMed Web of Science ®Google Scholar
• Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010;107(5):2177-82
   Google Scholar
• Ban S, Mino M, Nishioka NS, et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett’s esophagus. Am J Surg Pathol 2004;28(11):1466-73
   PubMed Web of Science ®Google Scholar
• Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49(1):1-7
   PubMed Web of Science ®Google Scholar
• van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60(6):765-73
   PubMed Web of Science ®Google Scholar
• Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145(1):87-95
   PubMed Web of Science ®Google Scholar
• Al-Kasspooles MF, Hill HC, Nava HR, et al. High-grade dysplasia within Barrett’s esophagus: controversies regarding clinical opinions and approaches. Ann Surg Oncol 2002;9(3):222-7
   Google Scholar
• Williams VA, Watson TJ, Herbella FA, et al. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J Gastrointest Surg 2007;11(12):1589-97
   Google Scholar
• Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360(22):2277-88
   PubMed Web of Science ®Google Scholar
• Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143(2):336-46
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Baldus SE, Schroder W, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006;38(2):149-56
   PubMed Web of Science ®Google Scholar
• Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 2008;112(5):1020-7
   Google Scholar
• Thompson SK, Bartholomeusz D, Jamieson GG. Sentinel lymph node biopsy in esophageal cancer: should it be standard of care? J Gastrointest Surg 2011;15(10):1762-8
   Google Scholar
• Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011;60(11):1449-72
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009;22(12):1555-63
   Google Scholar
• Bollschweiler E, Holscher AH, Metzger R, et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011;92(6):2020-7
   Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339(27):1979-84
   PubMed Web of Science ®Google Scholar
• Matsuyama J, Doki Y, Yasuda T, et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007;141(5):570-80
   Google Scholar
• Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12(7):681-92
   PubMed Web of Science ®Google Scholar
• Korst RJ, Kansler AL, Port JL, et al. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg 2006;82(2):480-4. discussion 4-5
   Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20
   PubMed Web of Science ®Google Scholar
• Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009;58(1):127-43
   PubMed Web of Science ®Google Scholar
• zum Buschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011;52(8):1189-96
   PubMed Web of Science ®Google Scholar
• van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys 2008;8:3
   Google Scholar
• Curtis NJ, Noble F, Bailey IS, et al. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol 2014;109(3):202-7
   PubMed Web of Science ®Google Scholar
• Collette L, Bosset J-F, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? a trial of the european organisation for research and treatment of cancer radiation oncology group. J Clin Oncol 2007;25(28):4379-86
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
   PubMed Web of Science ®Google Scholar
• Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18(2):546-54
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proceedings of the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; 2008
   Google Scholar
• Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Canc Res 2011;1(4):482-97
   PubMed Web of Science ®Google Scholar
• Marsh D, Suchak K, Moutasim KA, et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 2011;223(4):470-81
   PubMed Web of Science ®Google Scholar
• Naber HP, ten Dijke P, Pardali E. Role of TGF-beta in the tumor stroma. Curr Cancer Drug Targets 2008;8(6):466-72
   Google Scholar
• Bonafoux D, Lee WC. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin Ther Pat 2009;19(12):1759-69
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116(7):1955-62
   PubMed Web of Science ®Google Scholar
• Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Translat Med 2012;10:1
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305(19):1969-77
   PubMed Web of Science ®Google Scholar